RT Book, Section
A1 Ferreira, João Pedro
A1 Sharma, Kavita
A1 Butler,  Javed
A2 Fuster, Valentin
A2 Narula, Jagat
A2 Vaishnava, Prashant
A2 Leon, Martin B.
A2 Callans, David J.
A2 Rumsfeld, John S.
A2 Poppas, Athena
SR Print(0)
ID 1204744812
T1 Diagnosis and Management of Heart Failure with Preserved Ejection Fraction – Updated April 2023
T2 Fuster and Hurst's The Heart, 15e
YR 2022
FD 2022
PB McGraw-Hill Education
PP New York, NY
SN 9781264257560
LK accessmedicine.mhmedical.com/content.aspx?aid=1204744812
RD 2024/04/19
AB Content  UpdateSemaglutide  in  Patients  with  Heart  failure  with  Preserved  Ejection  Fraction  and  Obesity:  a  New  Addition  to  the  Armamentarium  of  Heart  Failure  TherapiesThe  STEP-HFpEF  Trial  was  a  phase  3  clinical  trial  designed  to  assess  the  impact  of  semaglutide,  a  glucagon-like  peptide  1  receptor  agonist  (GLP1ra),  on  both  heart  failure  quality-of-life  metrics  and  reduction  in  weight  in  those  with  heart  failure  with  preserved  ejection  fraction  (HFpEF)  and  obesity.  Read  More